Daniel Flesch, Sun-Yee Cheung, Jurema Schmidt, Matthias Gabler, Pascal Heitel, Jan Kramer, Astrid Kaiser, Markus Hartmann, Mara Lindner, Kerstin Lüddens-Dämgen, Jan Heering, Christina Lamers, Hartmut Lüddens, Mario Wurglics, Eugen Proschak, Manfred Schubert-Zsilavecz, Daniel Merk Nonacidic Farnesoid X Receptor Modulators. 2017, Journal of Medicinal Chemistry
Daniel Flesch, Manfred Schubert-Zsilavecz Synthesis of imidazo[1,2-a]pyridines in a sequential one-pot Groebke-Blackburn modification using 2-aminopyridines, aldehydes and amines 2015, Die Pharmazie
Daniel Flesch, Matthias Gabler, Andreas Lill, Roberto Carrasco Gomez, Ramona Steri, Gisbert Schneider, Holger Stark, Manfred Schubert-Zsilavecz, Daniel Merk Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties 2015, Bioorganic & medicinal chemistry
Tilo Knape, Daniel Flesch, Laura Kuchler, Lisa Sha, Annika K Giegerich, Sandra Labocha, Mario Wurglics, Manfred Schubert-Zsilavecz, Eugen Proschak, Bernhard Brüne, Michael J. Parnham, Andreas von Knethen Identification and characterisation of a prototype for a new class of competitive PPARgamma antagonists 2015, European journal of pharmacology
Daniel Flesch, Julia Ness, Christina Lamers, Friederike Dehm, Sven Popella, Isabella Ogorek, Martina Hieke, Gerd Dannhardt, Oliver Werz, Sascha Weggen, Manfred Schubert-Zsilavecz SAR-studies of gamma-secretase modulators with PPARgamma-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer's disease 2015, Bioorganic & medicinal chemistry letters
Daniel Merk, Christina Lamers, Julia Weber, Daniel Flesch, Matthias Gabler, Eugen Proschak, Manfred Schubert-Zsilavecz Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands 2014, Bioorganic & Medicinal Chemistry
Daniel Merk, Matthias Gabler, Roberto Carrasco Gomez, Daniel Flesch, Thomas Hanke, Astrid Kaiser, Christina Lamers, Oliver Werz, Gisbert Schneider, Manfred Schubert-Zsilavecz Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR) 2014, Bioorganic & medicinal chemistry
Manfred Schubert-Zsilavecz, Daniel Flesch Phosphodiesterasen - Attraktive Ziele für Arzneistoffe 2014, Pharmazeutische Zeitung
Daniel Flesch, Daniel Merk, Christina Lamers, Manfred Schubert-Zsilavecz Novel prostaglandin receptor modulators--part II: EP receptor modulators; a patent review (2002 - 2012) 2013, Expert opinion on therapeutic patents
Daniel Flesch, Manfred Schubert-Zsilavecz Orale Antidiabetika in der klinischen Entwicklung 2013, Pharmakon
Daniel Flesch, Manfred Schubert-Zsilavecz, Daniel Merk Novel prostaglandin receptor modulators: a patent review (2002 - 2012) - part I: non-EP receptor modulators 2012, Expert opinion on therapeutic patents
Daniel Flesch, Manfred Schubert-Zsilavecz Tumortherapeutika vor der Zulassung 2012, Pharmazeutische Zeitung
